Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1016/J.IJPHARM.2024.124507 | ||||
| Año | 2024 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Epigallocatechin-3-gallate (EGCG) exhibits several pharmacological activities with potential benefits for human health, however, it has low oral bioavailability. A promising approach is to transport EGCG in a nanostructured system to protect it until it reaches the site of action and also allow combining chemotherapy with phototherapy to improve its therapeutic efficiency. The aim of this work was to synthesize GNR@mSiO2-NH2/EGCG and characterize the adsorption process, its antioxidant activity, properties and photothermal stability, for its potential use in chemo-photothermal therapy. The nanosystem presented good encapsulation efficiency (19.2 %) and EGCG loading capacity (6.0 %). The DPPH center dot free radical scavenging capacity (RSA) and chelating activity of the nanosystem was 60.7 +/- 6.9% and 71.0 +/- 6.4% at an EGCG equivalent concentration of 1 mu g/mL and 30 mu g/ mL, respectively. The core-shell NPs presented a good photothermal transduction efficiency of 17 %. EGCG free, as well as its RSA and chelating activity, remained stable after NIR irradiation (808 nm, 7 W/cm2). The morphology of GNR@mSiO2 remained intact after being irradiated with NIR, however, ultrasmall gold NPs could be observed, probably a product of photocracking of GNR. In summary, the nanosystem has good antioxidant activity, photothermal stability, and photothermal transduction ability making it potentially useful for chemophotothermal therapy.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 4 | KOGAN-BOCIAN, MARCELO JAVIER | Hombre |
Universidad de Chile - Chile
Adv Ctr Chron Dis ACCDiS - Chile Centro Avanzado de Enfermedades Crónicas - Chile |
| 4 | Valenzuela, Javier Morales | - |
Universidad de Chile - Chile
|
| 6 | Morales Valenzuela, Javier | - |
Universidad de Chile - Chile
|
| 7 | Avendano-Godoy, Javier | - |
Universidad de Chile - Chile
Adv Ctr Chron Dis ACCDiS - Chile Univ Grenoble Alpes - Francia Centro Avanzado de Enfermedades Crónicas - Chile Universite Grenoble Alpes - Francia |
| 8 | Cattoen, Xavier | - |
Univ Grenoble Alpes - Francia
Universite Grenoble Alpes - Francia |
| Fuente |
|---|
| FONDECYT |
| National Fund for Scientific and Technological Development (FONDECYT) |
| Fondo Nacional de Desarrollo Científico y Tecnológico |
| Financing Fund for Research Centers in Priority Areas (FONDAP) |
| Ministere de l'Europe et des Affaires-Campus France/EIFFEL EXCELLENCE |
| ANID/Scholarship Program/NATIONAL |
| Ministère de l'Europe et des Affaires-Campus |
| Agradecimiento |
|---|
| This work was supported by the National Fund for Scientific and Technological Development (FONDECYT) [Projects 1221145 and 1211482] and the Financing Fund for Research Centers in Priority Areas (FONDAP) [Projects 15130011 and 1523A0008] . Javier Avendano- Godoy is grateful to ANID/Scholarship Program/NATIONAL DOCTORATE/2020-21202096 and Ministere de l'Europe et des Affaires-Campus France/EIFFEL EXCELLENCE SCHOLARSHIP/116702Q (2022-2023) . |
| This work was supported by the National Fund for Scientific and Technological Development (FONDECYT) [Projects 1221145 and 1211482 ]. Javier Avenda\u00F1o-Godoy is grateful to ANID/Scholarship Program/NATIONAL DOCTORATE/2020-21202096 and Minist\u00E8re de l'Europe et des Affaires-Campus France/EIFFEL EXCELLENCE SCHOLARSHIP/116702Q (2022-2023). |
| This work was supported by the National Fund for Scientific and Technological Development (FONDECYT) [Projects 1221145 and 1211482 ]. Javier Avenda\u00F1o-Godoy is grateful to ANID/Scholarship Program/NATIONAL DOCTORATE/2020-21202096 and Minist\u00E8re de l'Europe et des Affaires-Campus France/EIFFEL EXCELLENCE SCHOLARSHIP/116702Q (2022-2023). |